Condition: Osteoarthritis, Knee · Sponsor: Scarcell Therapeutics S.A.S.
The company funding this study has developed an advanced therapy medicinal product (a cell therapy) from human donor cells which it wants to assess as a possible treatment for knee osteoarthritis (OA). Tissue from the gums of a human donor is used to make the study drug called allogeneic engineered Gingival Fibroblasts (aeGF). The purpose of this study is to evaluate the safety of a single injection of aeGF in the knee joint of participants with OA. aeGF have shown anti-inflammatory effects, pain relief and cartilage regeneration in animals and so are now being investigated as a treatment for OA in humans.
This description comes directly from the study's public registry record.
Sarah Sorrel (CEO) · +33611729481 · sarah.sorrel@scarcell.com
Caroline Stalla · +33 6 46 28 78 65 · caroline.stalla@scarcell.com
Always discuss trial participation with your own doctor first.
| Oxford University Hospitals NHS Foundation Trust (Nuffield Orthopaedic Centre, Oxford) | Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06690710